Table 3

Clinicopathological features
All patients (n=60) BRCA1 (n=3) BRCA2 (n=25) BRCAX (n=32) P-value
AGE AT DIAGNOSIS
Median 62.5 (30.1 - 85.6) 65.6 (49.5-80.1) 61 (31.0 - 85.7) 63.2 (30.1 - 81.8)
<60 yoa 26 (43.3%) 1 (33.3%) 11 (44.0%) 14 (43.8%)
>60 yoa 34 (56.7%) 2 (66.6%) 14 (56.0%) 18 (56.3%) NS
DISEASE SPECIFIC MORTALITY 35.0% 33.3% 40.0% 31.3%
SIDE
Right 36 (60.0%) 1 (33.3%) 17 (68.0%) 18 (56.2%)
Left 24 (40.0%) 2 (66.7%) 8 (32.0%) 14 (43.8%) NS
Unifocal 56 (93.3%) 3 (100%) 22 (88.0%) 31 (96.9%)
Multifocal 2 (3.3%) 0 2 (8.0%) 0
Bilateral 2 (3.3%) 0 1 (4.0%) 1 (3.1%) NS
HISTOLOGICAL SUBTYPE
Invasive Ductal Carcinoma - No special type 46 (76.7%) 2 (66.7%) 18 (72%) 28 (87.5%)
IDC with Micropapillary component 8 (13.3%) 0 6 (24%) 2 (6.3%)
Invasive Papillary Carcinoma 4 (6.7%) 1 (33.3%) 1 (4%) 2 (6.3%)
Invasive Lobular Carcinoma 2 (3.3%) 0 0 2 (6.3%) NS
BRE GRADE
1 2 (3.3%) 0 1 (4%) 1 (3.1%)
2 31 (51.7%) 0 12 (48%) 19 (59.4%)
3 27 (45.0%) 3 (100%) 12 (48%) 12 (37.5%) NS
ER STATUS (ALLRED 0-8)
0 1 (1.7%) 0 0 1 (3.3%)
1-5. 5 (8.6%) 1 (33.3%) 2 (8.0%) 2 (6.7%)
6-8. 52 (89.7%) 2 (66.7%) 23 (92.0%) 27 (90.0%)
NA 2 0 0 2 NS
PR STATUS (ALLRED 0-8)
0 5 (8.8%) 0 1 (4%) 4 (13.8%)
1-5. 8 (14.0%) 0 5 (20%) 3 (10.3%)
6-8. 44 (77.2%) 3 (100%) 19 (76%) 22 (75.9%)
NA 3 0 0 3 NS
HER2
Amplification 5 (9.1%) 0 2 (8.3%) 3 (10.7%)
Non-amplified 50 (90.9%) 3 (100%) 22 (91.7%) 25 (89.3%)
NA 5 0 1 4 NS
PHENOTYPE
Basal 1 (1.7%) 0 0 1 (3.3%)
Luminal 52 (89.7%) 3 (100%) 23 (92.0%) 26 (86.7%)
HER2 5 (8.6%) 0 2 (8.0%) 3 (10.0%)
NA 2 0 0 2 NS
TUMOUR SIZE
Median 17mm (2-50mm) 15mm (9-25mm) 17mm (6-40mm) 16 (2-50mm)
TUMOUR STAGE
T1a 1 (1.7%) 0 0 1 (3.1%)
T1b 8 (13.3%) 1 (33.3%) 4 (16.0%) 3 (9.4%)
T1c 31 (51.7%) 1 (33.3%) 10 (40.0%) 19 (59.4%)
T2 19 (31.7%) 1 (33.3%) 11 (44.0%) 7 (21.9%)
T3 1 (1.7%) 0 0 1 NS
LYMPHOVASCULAR INVASION
Absent 32 (57.1%) 2 (66.7%) 14 (60.9%) 16 (53.3%)
Present 24 (42.9%) 1 (33.3%) 9 (39.1%) 14 (46.7%)
NA 4 0 2 2 NS
PERINEURAL INVASION
Absent 31 (56.4%) 3 (100%) 12 (50.0%) 16 (57.1%)
Present 24 (43.6%) 0 12 (50.0%) 12 (42.9%)
NA 5 0 1 4 NS
PAGET'S DISEASE OF NIPPLE
Absent 44 (84.6%) 2 (100%) 19 (86.4%) 23 (82.1%)
Present 8 (15.4%) 0 3 (13.6%) 5 (17.9%)
NA 8 1 3 4 NS
NODAL STATUS
Cases with nodes examined 46 (76.7%) 3 (100%) 20 (80.0%) 23 (71.9%)
Cases with positive nodes 20 (43.4%) 2 (66.7%) 9 (45.0%) 9 (39.1%) NS
Average numbers of nodes examined per case 12.9 (1-30) 16.3 (13-24) 15.9 (1-30) 10.1 (1-29)
NODAL STAGE
N0 26 (56.5%) 1 (33.3%) 11 (55.0%) 14 (60.1%)
N1 18 (39.1%) 2 (66.7%) 8 (40.0%) 8 (34.8%)
N2 2 (4.3%) 0 1 (5.0%) 1 (4.3%) NS
Cases with extranodal extension 8 (17.4%) 0 5 (25.0%) 3 (13.0%) NS
MARGINS
Clear 29 (48.3%) 1 (33.3%) 12 (48.0%) 16 (50.0%)
Involved 15 (25.0%) 0 6 (24.0%) 9 (28.1%)
Not assessable 16 (26.7%) 2 (66.7%) 7 (28.0%) 7 (21.9%) NS
DCIS
Absent 14 (25.0%) 0 7 (29.2%) 7 (24.1%)
NA 4 0 1 3
Present 42 (75.0%) 3 (100%) 17 (70.8%) 22 (75.9%) NS
Nuclear Grade
Low 2 (4.8%) 0 2 (11.8%) 0
Intermediate 26 (61.9%) 1 (33.3%) 10 (58.8%) 15 (68.0%)
High 14 (33.3%) 2 (66.7%) 5 (29.4%) 7 (31.8%) NS

NS – Not significant.

Deb et al.

Deb et al. BMC Cancer 2012 12:510   doi:10.1186/1471-2407-12-510

Open Data